Biobanking for COVID-19 research

作者：Patrizia Rovere-Querini, COVID-BioB Study Group, Cristina Tresoldi, Caterina Conte, Annalisa Ruggeri, Silvia Ghezzi, Rebecca De Lorenzo, Luigi di Filippo, Nicola Farina, Giuseppe A. Ramirez, Marco Ripa, Nicasio Mancini, Elisa Cantarelli, Laura Galli, Andrea Poli, Francesco De Cobelli, Chiara Bonini, Angelo A. Manfredi, Stefano Franchini, Marzia Spessot, Michele Carlucci, Lorenzo Dagna, Paolo Scarpellini, Alberto Ambrosio, Davide Di Napoli, Emanuele Bosi, Moreno Tresoldi, Adriano Lazzarin, Giovanni Landoni, Gianvito Martino, Alberto Zangrillo, Guido Poli, Antonella Castagna, Elisa Vicenzi, Massimo Clementi, Fabio Ciceri · 发表于：Panminerva Medica · 年份：2021 · DOI：10.23736/s0031-0808.20.04168-3 · 被引用次数：52 · 研究领域：COVID-19 Clinical Research Studies、Ethics in Clinical Research、SARS-CoV-2 detection and testing

BACKGROUND: Biobanks are imperative infrastructures, particularly during outbreaks, when there is an obligation to acquire and share knowledge as quick as possible to allow for implementation of science-based preventive, diagnostic, prognostic, and therapeutic strategies. METHODS: We established a COVID-19 biobank with the aim of collecting high-quality and well-annotated human biospecimens, in the effort to understand the pathogenic mechanisms underlying COVID-19 and identify therapeutic targets (COVID-BioB, NCT04318366). Here we describe our experience and briefly review the characteristics of the biobanks for COVID-19 that have been so far established. RESULTS: A total of 46,677 samples have been collected from 913 participants (63.3% males, median [IQR] age 62.2 [51.2-74.0] years) since the beginning of the program. Most patients (66.9%) had been admitted to hospital for COVID-19, with a median length of stay of 15.0 (9.0-27.0) days. A minority of patients (13.3% of the total) had been admitted for other reasons and subsequently tested positive for SARS-CoV-2. The remainder were managed at home after being seen at the Emergency Department. CONCLUSIONS: Having a solid research infrastructure already in place, along with flexibility and adaptability to new requirements, allowed for the quick building of a COVID-19 biobank that will help expand and share the knowledge of SARS-CoV-2.